Greece Country Drug Report 2019

Public expenditure

Understanding the costs of drug-related actions is an important aspect of drug policy. Some of the funds allocated by governments for expenditure on tasks related to drugs are identified as such in the budget (‘labelled’). Often, however, most drug-related expenditure is not identified (‘unlabelled’) and must be estimated using modelling approaches.

The mid-term national action plan on drugs for 2011-12 included an associated budget, providing comprehensive estimates of planned, labelled and executed drug-related expenditure.

During 2011-12, planned labelled drug-related expenditure amounted to approximately 0.07 % of gross domestic product. Available comparable data on executed expenditure are limited and relate mainly to the health sector; however, these data suggest that public austerity affected the financing of drug-related services, with indications that drug-related expenditure declined markedly in Greece between 2011 and 2014.


Greece main page

Methodological note: Analysis of trends is based only on those countries providing sufficient data to describe changes over the period specified. The reader should also be aware that monitoring patterns and trends in a hidden and stigmatised behaviour like drug use is both practically and methodologically challenging. For this reason, multiple sources of data are used for the purposes of analysis in this report. Caution is therefore required in interpretation, in particular when countries are compared on any single measure. Detailed information on methodology and caveats and comments on the limitations in the information set available can be found in the EMCDDA Statistical Bulletin.